Vivistim Two-Year Data Published in Neurology: 76% Responder Rate, Durable Stroke Recovery Gains
MOBI is trading near its 52-week low of $10.74 (9.7% above the low).
Summary
Mobia Medical published two-year follow-up data from its pivotal VNS-REHAB trial in Neurology, showing durable and clinically meaningful improvements in upper-limb motor function for chronic stroke survivors treated with Vivistim Paired VNS Therapy. The study reported a 76% responder rate, with average gains of +7.5 points on the Fugl-Meyer Assessment and +0.63 on the Wolf Motor Function Test, both exceeding established minimum clinically important differences. Patient-reported outcomes also showed significant improvements in activities of daily living, hand function, and quality of life. A subset of 16 participants demonstrated sustained benefits at three years, and some patients continued to improve between years one and two. This publication adds to the body of evidence supporting Vivistim's efficacy and durability, potentially accelerating adoption and reimbursement. The data arrives two months after the company's IPO and strong Q1 revenue growth, reinforcing the commercial thesis.
At the time of this announcement, MOBI was trading at $11.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $384.7M. The 52-week trading range was $10.74 to $15.29. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.